Association between oral fluoroquinolones and seizures

Neurology

Volumn 86, Issue 18, 2016, Pages 1708-1715

  Chui, Celine S L ^a   Chan, Esther W ^a   Wong, Angel Y S ^a   Root, Adrian ^b   Douglas, Ian J ^b   Wong, Ian C K ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; FEMALE; HONG KONG; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RISK FACTOR; SEIZURE; SENSITIVITY ANALYSIS; UNITED KINGDOM; AGED; FOLLOW UP; META ANALYSIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK; SEIZURES; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HONG KONG; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK; SEIZURES; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

EID: 84966550910     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002633     Document Type: Article

References (30)

1. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary, 70th ed. London: British Medical Journal Publishing Group; 2015
2. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001; 35: 1194-1198
3. Darwish T. Ciprofloxacin-induced seizures in a healthy patient. N Z Med J 2008; 121: 104-105
4. Quigley CA, Lederman JR. Possible gatifloxacin-induced seizure. Ann Pharmacother 2004; 38: 235-237
5. Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA. Seizures associated with ofloxacin therapy. Clin Infect Dis 1995; 21: 1504-1506
6. Tattevin P, Messiaen T, Pras V, Ronco P, Biour M. Confusion and general seizures following ciprofloxacin administration. Nephrol Dial Transpl 1998; 13: 2712-2713
7. Marinella MA. Myoclonus and generalized seizures associated with gatifloxacin treatment. Arch Intern Med 2001; 161: 2261-2262
8. Bird SB, Orr PG, Mazzola JL, Brush DE, Boyer EW. Levofloxacin-related seizure activity in a patient with Alzheimer?s disease: assessment of potential risk factors. J Clin Psychopharmacol 2005; 25: 287-288
9. Koussa SF, Chahine SL, Samaha EI, Riachi MA. Generalized status epilepticus possibly induced by gatifloxacin. Eur J Neurol 2006; 13: 671-672
10. Lahmek P, Michel L, Meunier N, Aubin HJ. A seizure attributed to ofloxacine in a woman undergoing detoxification for alcohol dependence. Case Rep Med 2009; 2009: 705635
11. Famularo G, Pizzicannella M, Gasbarrone L. Levofloxacin and seizures: what risk for elderly adults? J Am Geriatr Soc 2014; 62: 2018-2019
12. Gervasoni C, Cattaneo D, Falvella FS, et al. Levofloxacininduced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics. Eur J Clin Pharmacol 2013; 69: 1611-1613
13. Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in Vitro model. Antimicrob Agents Chemother 1998; 42: 1831-1836
14. Akahane K, Sekiguchi M, Une T, Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989; 33: 1704-1708
15. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother 1990; 26(suppl B): 219-225
16. Chui CS, Man KK, Cheng CL, et al. An investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study. J Antimicrob Chemother 2014; 69: 2563-2567
17. Man KK, Ip P, Hsia Y, et al. ADHD drug prescribing trend is increasing among children and adolescents in Hong Kong. J Atten Disord Epub 2014 Jul 3
18. He Y, Chan EW, Man KK, et al. Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study. Drug Saf 2014; 37: 711-721
19. Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 2015; 149: 586-595.e3
20. Man KK, Chan EW, Coghill D, et al. Methylphenidate and the risk of trauma. Pediatrics 2015; 135: 40-48
21. Wong AYS, Root A, Douglas IJ, et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016; 352: h6926
22. Campbell J, Dedman DJ, Eaton SC, Gallagher AM, Williams TJ. Is the CPRD GOLD population comparable to the UK population? Pharmacoepidemiol Drug Saf 2013; 22: 280-281
23. Rodriguez LAG, Gutthann SP. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425
24. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ 2013; 346: f1936
25. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25: 1768-1797
26. Douglas IJ, EVans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009; 6: e1000154
27. Farrington CP, Anaya K, Whitaker H, Hocine MN, Douglas IJ, Smeeth L. Self-controlled case series analysis with event-dependent observation periods. J Am Stat Assoc 2010; 106: 417-426
28. Musonda P, Farrington CP, Whitaker HJ. Sample sizes for selfcontrolled case series studies. Stat Med 2006; 25: 2618-2631
29. Serrano-Castro PJ, Quiroga-Subirana P, Payan-Ortiz M, Fernandez-Perez J. The expanding spectrum of febrile infection-related epilepsy syndrome (FIRES). Seizure 2013; 22: 153-155
30. Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC. Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol 2009; 65: 959-962